Clinical trials
Phase 4 Leukemia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 4 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Unknown status | 6 |
| Terminated | 4 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| Pfizer | 3 |
| Ain Shams University | 1 |
| Amgen | 1 |
| Children's Hospital of Michigan | 1 |
| Chinese PLA General Hospital | 1 |
| Cytovia, Inc. | 1 |
| East Valley Hematology and Oncology Medical Group | 1 |
| Federal University of Minas Gerais | 1 |
| Fox Chase Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia | 30 |
| Leukemia, Myeloid, Acute | 7 |
| Lymphoma | 5 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 |
| Febrile Neutropenia | 3 |
| Neoplasms | 3 |
| Recurrence | 3 |
| Carcinoma, Hepatocellular | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
Trials
Showing 51 to 30 of 30. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.